Trial Profile
Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma, a Multicentric, Single Arm, Open Label Phase II Clinical Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2022
Price :
$35
*
At a glance
- Drugs Tucidinostat (Primary) ; Etoposide; Prednisone; Thalidomide
- Indications T-cell lymphoma
- Focus Therapeutic Use
- 18 Apr 2022 Status changed from recruiting to completed, according to Results published in the American Journal of Hematology.
- 18 Apr 2022 Results published in the American Journal of Hematology
- 08 Sep 2017 New trial record